查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1632597

全球核酸治療藥物 CDMO 市場：市場規模、佔有率和趨勢分析（按類型、服務、最終用途、應用、地區和細分，2025-2030 年）

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service (Process Development and Optimization), By End-use, By Application, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 170 Pages | 商品交期: 2-10個工作天內

價格

核酸治療 CDMO 市場成長與趨勢：

根據Grand View Research, Inc.的一份新報告，到2030年全球核酸治療CDMO市場預計將達到338.6億美元。

預計 2025 年至 2030 年期間市場複合年成長率為 14.20%。推動市場發展的主要因素是對核酸療法的需求不斷增加、核酸技術的進步以及 FDA 對核酸療法核准的增加，這些因素推動了對具有成本效益的合約開發和製造服務的需求。

生物技術、製藥和學術機構對基因治療研發的投資和興趣不斷增加，推動了對 CDMO 服務的需求。 CDMO 在基因治療製造中發揮關鍵作用。例如，Catalent 作為 Sarepta Therapeutics 的商業製造合作夥伴，在推動其基因治療解決方案方面發揮關鍵作用。

mRNA疫苗在應對COVID-19大流行中的成功證明了核酸療法的潛力，並刺激了該領域的進一步研究和投資。例如，賽諾菲於 2022 年 3 月宣布，計劃在未來幾年內撥款 10.2 億美元（9.35 億歐元）用於法國傳訊RNA疫苗的開發。賽諾菲將在 2026 年之前進行投資，這是 2021 年 6 月宣布的 20 億歐元國際投資舉措的一部分。該舉措旨在推進該公司的 mRNA 策略。此類融資情境將會促進市場成長。

此外，預計未來幾年 CDMO 收購和合作的增加將推動核酸治療 CDMO 市場的成長。例如，2022 年 5 月，eureKARE 達成了一項價值 1.6098 億美元（1.5 億歐元）的合併協議，創建了一個細胞和基因治療受託製造廠商(CDMO)。

該公司成立了一家特殊目的收購公司（SPAC）eureKING，目標是合併三家歐洲合約開發和受託製造廠商（CDMO）。此外，2022 年 4 月，FUJIFILM收購了加州 Atara Biotherapeutics, Inc. 的一家專門從事細胞療法的製造工廠，擴大了其先進療法合約開發和受託製造廠商(CDMO) 的組合。預計這些措施將促進市場成長。

核酸治療 CDMO 市場：概述

  • 預計 RNA 治療領域將在 2024 年佔據最大的收益佔有率。基於 RNA 的治療方法（主要是 mRNA）具有多種治療多種疾病的方法。它們可以經過設計來生產多種治療性蛋白質，從而應用於多個治療領域。
  • 預計未來幾年基因治療藥物領域將經歷顯著的市場成長。這是由於基因治療藥物的臨床成功，有助於擴大基因治療藥物的適應症。
  • 2024 年，製造服務部門佔據市場主導地位，佔總收入佔有率的 38.37% 以上。推動該行業成長的關鍵挑戰包括複雜的製造流程、可擴展性和生產方面的挑戰以及成本效率。
  • 由於對創新治療方法研發的大量投資，生技公司在 2024 年佔據了超過 58% 的收益佔有率。
  • 在 2024 年核酸治療 CDMO 市場中，北美佔據最大的收益佔有率，為 40.24%。大量的投資和資金、強大的學術研究機構以及不斷擴大的全球 CDMO 格局正在推動該地區的成長。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

3. 核酸治療 CDMO 市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 臨床實驗數量分析（2024 年）
    • 各地區臨床實驗總數（2024 年）
    • 各階段臨床實驗總數（2024 年）
    • 依研究設計分類的臨床實驗總數（2024 年）
    • 按主要治療領域分類的臨床實驗總數（2024 年）
  • 市場分析工具
    • 波特五力分析
    • PESTEL 與 SWOT 分析
    • COVID-19影響分析

第 4 章 核酸治療 CDMO 市場：按類型估計和趨勢分析

  • 細分儀表板
  • 全球核酸治療 CDMO 市場：波動分析
  • 全球核酸治療 CDMO 市場：市場規模與趨勢分析（按類型分類）（2018-2030 年）
  • 基因治療
  • 基於RNA的療法

第 5 章 核酸治療 CDMO 市場：按服務分類的估計和趨勢分析

  • 細分儀表板
  • 全球核酸治療 CDMO 市場：波動分析
  • 全球核酸治療 CDMO 市場：按服務分類的市場規模和趨勢分析（2018-2030 年）
  • 製程開發與最佳化
  • 製造服務
  • 分析和品管服務

第 6 章 核酸治療 CDMO 市場：依最終用途的估計與趨勢分析

  • 細分儀表板
  • 全球核酸治療 CDMO 市場：波動分析
  • 全球核酸治療 CDMO 市場：按最終用途分類的市場規模和趨勢分析（2018-2030 年）
  • 製藥公司
  • 政府及學術研究機構
  • 生技公司

第 7 章 核酸治療 CDMO 市場：按應用分類的估計和趨勢分析

  • 細分儀表板
  • 全球核酸治療 CDMO 市場：波動分析
  • 全球核酸治療 CDMO 市場：市場規模與趨勢分析（按應用分類）（2018-2030 年）
  • 罕見疾病
  • 遺傳性疾病
  • 感染疾病
  • 其他

第 8 章 核酸治療 CDMO 市場：按地區分類的估計和趨勢分析

  • 區域市場儀表板
  • 全球市場概況：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 市場參與企業分類
    • 市場領導
    • 新興企業
  • 競爭市場佔有率/估值分析（2024 年）
  • 公司簡介
    • Agilent Technologies, Inc
    • Curia Global, Inc.
    • Ajinomoto Co., Inc.
    • Danaher Corporation
    • KNC Laboratories Co., Ltd.
    • LGC Limited
    • Merck KGaA
    • WuXi AppTec
    • BIOSPRING
    • Exothera
Product Code: GVR-4-68040-125-4

Nucleic Acid Therapeutics CDMO Market Growth & Trends:

The global nucleic acid therapeutics CDMO market size is anticipated to reach USD 33.86 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 14.20% from 2025 to 2030. The market's growth is primarily attributed to factors such as increasing demand for nucleic acid therapeutics, advancements in nucleic acid technologies, and rising FDA approvals of nucleic acid therapeutics, propelling the need for cost-effective contract development and manufacturing services.

Growing investment and interest in gene therapy research and development by biotechnology companies, pharmaceutical firms, and academic institutions are driving the demand for CDMO services. CDMOs have played a crucial role in gene therapy manufacturing. For instance, Catalent has taken on the primary role as the commercial manufacturing partner for Sarepta Therapeutics in their efforts to advance gene therapy solutions.

The success of mRNA vaccines in responding to the COVID-19 pandemic has showcased the potential of nucleic acid therapeutics, stimulating further research and investment in this field. For instance, in March 2022, Sanofi announced that it plans to allocate USD 1.02 billion (935 million euros) for the development of messenger RNA vaccines in France over the coming years. Sanofi intends to allocate this investment until 2026 as a part of a 2-billion-euro global investment initiative unveiled in June 2021. This initiative is designed to expedite the company's mRNA strategy. Such increased funding scenarios drive market growth.

Furthermore, increasing incidences of CDMO acquisitions and partnerships are expected to accelerate the market growth for nucleic acid therapeutics CDMO in the coming years. For instance, in May 2022, eureKARE initiated a merger worth USD 160.98 million (€150 million) to create a cell & gene therapy contract development and manufacturing organization (CDMO).

The company has established eureKING, a Special Purpose Acquisition Company (SPAC), with the aim of merging three European Contract Development and Manufacturing Organizations (CDMOs) into a unified entity. In another instance, in April 2022, Fujifilm broadened its Advanced Therapies Contract Development and Manufacturing Organization (CDMO) portfolio by acquiring a specialized cell therapy manufacturing facility from Atara Biotherapeutics, Inc. located in California. Such initiatives are expected to boost market growth.

Nucleic Acid Therapeutics CDMO Market Report Highlights:

  • The RNA-based therapies segment held the largest revenue share in 2024. RNA-based therapies, mainly mRNA, offer versatility in addressing various diseases. They can be designed to produce a variety of therapeutic proteins, making them applicable to diverse therapeutic areas.
  • The gene therapy segment is expected to show significant market growth in the coming years. This is attributed to the clinical success of gene therapies, which have helped in expanding indications of gene therapies.
  • In 2024, the manufacturing services segment dominated the market, accounting for over 38.37% of the total revenue share. Key factors contributing to segment growth include complex manufacturing processes, scale-up & production challenges, and cost efficiency.
  • The biotechnology companies held a major revenue share of over 58% in 2024 due to substantial investments in the research and development of innovative therapies.
  • North America held the largest revenue share of 40.24% in the nucleic acid therapeutic CDMO market in 2024. Substantial investments and funding support, strong academic and research institutions, and global expansion of CDMOs drive regional growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Purchased Database
    • 1.3.3. GVR's Internal Database
    • 1.3.4. Secondary Sources
    • 1.3.5. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives
    • 1.9.1. Objective - 1
    • 1.9.2. Objective - 2
    • 1.9.3. Objective - 3
    • 1.9.4. Objective - 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Nucleic Acid Therapeutics CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising incidence of genetic disorders across the globe
      • 3.2.1.2. Robust expansion of the genomics research sector and strong traction gained by custom oligonucleotides
      • 3.2.1.3. Increasing demand for one-stop-shop CDMOs and growing foreign direct investments in nucleic acid therapeutics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Limited outsourcing by big pharmaceutical and biopharmaceutical companies
      • 3.2.2.2. Stringent regulatory framework
  • 3.3. Clinical Trials Volume Analysis, 2024
    • 3.3.1. Total Number of Clinical Trials, by Region (2024)
    • 3.3.2. Total Number of Clinical Trials, by Phase (2024)
    • 3.3.3. Total Number of Clinical Trials, by Study Design (2024)
    • 3.3.4. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
  • 3.4. Market Analysis Tools
    • 3.4.1. Porter's Five Forces Analysis
    • 3.4.2. PESTEL by SWOT Analysis
    • 3.4.3. COVID-19 Impact Analysis

Chapter 4. Nucleic Acid Therapeutics CDMO Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
  • 4.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Gene Therapy
    • 4.4.1. Gene Therapy Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.5. RNA-based Therapies
    • 4.5.1. RNA-based Therapies Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 5. Nucleic Acid Therapeutics CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
  • 5.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 5.4. Process Development and Optimization
    • 5.4.1. Process Development and Optimization Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 5.5. Manufacturing Services
    • 5.5.1. Manufacturing Services Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 5.6. Analytical and Quality Control Services
    • 5.6.1. Analytical and Quality Control Services Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 6. Nucleic Acid Therapeutics CDMO Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
  • 6.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical Companies
    • 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.5. Government & Academic Research Institutes
    • 6.5.1. Government & Academics Research Institutes Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 6.6. Biotech Companies
    • 6.6.1. Biotech Companies Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 7. Nucleic Acid Therapeutics CDMO Market: Application Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
  • 7.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, Application, 2018 to 2030 (USD Million)
  • 7.4. Rare Diseases
    • 7.4.1. Rare Diseases Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 7.5. Genetic Disorders
    • 7.5.1. Genetic Disorders Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 7.6. Infectious Diseases
    • 7.6.1. Infectious Diseases Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 8. Nucleic Acid Therapeutics CDMO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Dashboard
  • 8.2. Global Regional Market Snapshot
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Mexico Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. UK Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Germany Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. France Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Italy Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Spain Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Denmark Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Sweden Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Norway Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.6.2. China
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. China Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.6.3. Japan
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Japan Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. India Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Australia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. South Korea Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Thailand Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Brazil Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. South Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. UAE Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Competitive Market Share/Assessment Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. Agilent Technologies, Inc
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Curia Global, Inc.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Ajinomoto Co., Inc.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Danaher Corporation
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. KNC Laboratories Co., Ltd.
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. LGC Limited
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Merck KGaA
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. WuXi AppTec
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. BIOSPRING
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Exothera
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 4 Global Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 5 Global Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 6 Global Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 7 Global Nucleic Acid Therapeutics CDMO, by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 10 North America Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 11 North America Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 12 North America Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 13 U.S. Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 15 U.S. Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 16 U.S. Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 17 Canada Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 18 Canada Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 19 Canada Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Canada Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 21 Mexico Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 22 Mexico Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 23 Mexico Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Mexico Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 25 Europe Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 26 Europe Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 27 Europe Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 28 Europe Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 29 Europe Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 30 Germany Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 31 Germany Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 32 Germany Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 33 Germany Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 34 UK Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 35 UK Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 36 UK Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 37 UK Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 38 France Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 39 France Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 40 France Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 41 France Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 42 Italy Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 43 Italy Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 44 Italy Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Italy Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 46 Spain Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 47 Spain Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 48 Spain Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 49 Spain Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 50 Denmark Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 51 Denmark Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 52 Denmark Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 53 Denmark Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 54 Sweden Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 55 Sweden Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 56 Sweden Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 57 Sweden Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 58 Norway Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 59 Norway Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 60 Norway Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 61 Norway Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 67 China Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 68 China Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 69 China Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 70 China Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 71 Japan Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 72 Japan Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 73 Japan Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 74 Japan Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 75 India Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 76 India Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 77 India Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 78 India Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 79 South Korea Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 80 South Korea Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 81 South Korea Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 82 South Korea Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 83 Australia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 84 Australia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 85 Australia Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 86 Australia Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 87 Thailand Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 88 Thailand Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 89 Thailand Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 90 Thailand Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 91 Latin America Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 92 Latin America Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 93 Latin America Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 94 Latin America Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 95 Latin America Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 96 Brazil Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 97 Brazil Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 98 Brazil Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 99 Brazil Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 100 Argentina Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 101 Argentina Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 102 Argentina Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 103 Argentina Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 109 South Africa Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 110 South Africa Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 111 South Africa Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 112 South Africa Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 117 UAE Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 118 UAE Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 119 UAE Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 120 UAE Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 124 Kuwait Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Nucleic Acid Therapeutics CDMO, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Nucleic Acid Therapeutics CDMO, for Gene Therapy, 2018 - 2030 (USD Million)
  • Fig. 13 Global Nucleic Acid Therapeutics CDMO, for RNA-based Therapies, 2018 - 2030 (USD Million)
  • Fig. 14 Global Nucleic Acid Therapeutics CDMO, for Process Development and Optimization, 2018 - 2030 (USD Million)
  • Fig. 15 Global Nucleic Acid Therapeutics CDMO, for Manufacturing Services, 2018 - 2030 (USD Million)
  • Fig. 16 Global Nucleic Acid Therapeutics CDMO, for Analytical and Quality Control Services, 2018 - 2030 (USD Million)
  • Fig. 17 Global Nucleic Acid Therapeutics CDMO, for Others, 2018 - 2030 (USD Million)
  • Fig. 18 Global Nucleic Acid Therapeutics CDMO, for Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 19 Global Nucleic Acid Therapeutics CDMO, for Government & Academic Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 20 Global Nucleic Acid Therapeutics CDMO, for Biotech Companies, 2018 - 2030 (USD Million)
  • Fig. 21 Global Nucleic Acid Therapeutics CDMO, for Rare Diseases, 2018 - 2030 (USD Million)
  • Fig. 22 Global Nucleic Acid Therapeutics CDMO, for Genetic Disorders, 2018 - 2030 (USD Million)
  • Fig. 23 Global Nucleic Acid Therapeutics CDMO, for Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig. 24 Global Nucleic Acid Therapeutics CDMO, for Others, 2018 - 2030 (USD Million)
  • Fig. 25 Regional Outlook, 2024 & 2030
  • Fig. 26 North America Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Canada Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Mexico Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Europe Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Germany Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 UK Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 France Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Italy Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Spain Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Denmark Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Sweden Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Norway Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Asia Pacific Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Japan Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 China Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 India Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Australia Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 South Korea Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Latin America Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Brazil Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Argentina Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Middle East and Africa Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 South Africa Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Saudi Arabia Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 UAE Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Kuwait Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)